CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer

Published:2012-09-25 Issue:9 Volume:7 Page:e45865
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Aomatsu Naoki,Yashiro Masakazu,Kashiwagi Shinichiro,Takashima Tsutomu,Ishikawa Tetsuro,Ohsawa Masahiko,Wakasa Kenichi,Hirakawa Kosei

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study;British Journal of Clinical Pharmacology;2024-08-07

2. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer;Breast Cancer Research and Treatment;2024-07-17

3. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer;2024-03-27

4. A novel approach for transforming breast cancer stem cells into endothelial cells;Experimental and Therapeutic Medicine;2023-12-21

5. Molecular Phenotypes of Endothelial Cells in Malignant Tumors;Biomarkers of the Tumor Microenvironment;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP